Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 11, 2026
Synlogic, Inc. (SYBX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $543,000.
Revenue
$0
Net income
$-543,000
-2.6% vs year-ago quarter
Operating cash flow
$-922,000
-131.1% vs year-ago quarter
Free cash flow
$-923,000
-62.5% vs year-ago quarter
EPS
$-0.04
+0.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
12.25M
+4.7% vs year-ago quarter
Net cash
$18.86M
Q4 FY2024
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SYBX (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Winchester, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1527599
- Former names
- Mirna Therapeutics, Inc. (until Aug 25, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$1.0M | -$1.3M | -$1.3M | -$991,000 | -$777,000 |
| Net income | -$543,000 | $681,000 | $1.5M | -$2.3M | -$529,000 |
| Diluted EPS | -$0.04 | $0.05 | $0.12 | -$0.19 | -$0.04 |
| Operating cash flow | -$922,000 | -$563,000 | -$923,000 | -$1.4M | -$399,000 |
| Free cash flow | — | — | -$923,000 | -$1.4M | -$399,000 |
| Total assets | $13.5M | $14.6M | $15.4M | $16.6M | $17.4M |
| Stockholders' equity | $12.0M | $12.6M | $11.9M | $10.3M | $12.6M |
| Cash and investments | $13.2M | $14.1M | $14.7M | $15.6M | $17.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Change in control, Regulation FD disclosure
|
Jul 29, 2026 | Jul 27, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | Apr 30, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 12, 2026 | Dec 31, 2025 |
| 8-K/A |
Amended current report
Listing notice, Other events
|
Jan 29, 2026 | Jan 16, 2026 |
All 627 Synlogic, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.